{
    "nct_id": "NCT02541929",
    "title": "Fish Oil Brain Delivery Study",
    "status": "COMPLETED",
    "last_update_time": "2020-03-29",
    "description_brief": "Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure and function of brain cells.\n\nDHA fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. It is not known how much dietary fish oil can get into the human brain. Thus, exploring fish oil delivery in human brains is critical for designing appropriate interventions.",
    "description_detailed": "* The investigators goal is to study how different people deliver DHA to the brain.\n* The study will only require two visits six months apart and involve taking DHA during these 6 months.\n* Participants will receive DHA supplements for the study duration and a compensation for each study visit.\n* Blood and cerebrospinal fluid levels of DHA will be measured before and after taking DHA.\n* Brain imaging by MRI will be obtained at baseline and at conclusion of study\n* This study will help us learn how much of the ingested DHA goes to the brain.",
    "phase": [
        "PHASE2",
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "OTHER",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Docosahexaenoic acid (DHA) \u2014 an omega-3 long\u2011chain polyunsaturated fatty acid (fish oil)"
    ],
    "placebo": [
        "Not specified"
    ],
    "explanation_target": [
        "Reason: The described intervention is docosahexaenoic acid (DHA), an omega\u20113 long\u2011chain polyunsaturated fatty acid found in fish oil; DHA is a nutritional/small\u2011molecule fatty acid (not a biologic such as a monoclonal antibody) and does not specifically target amyloid or tau pathology. \ue200cite\ue202turn1search12\ue202turn0search0\ue201",
        "Act: The trial title and description focus on DHA fish oil brain delivery and prior animal studies showing cognitive benefit; the stated aim is to explore delivery into the human brain to inform cognitive intervention design \u2014 an intent to improve/assess cognitive effects rather than to modify a specific Alzheimer\u2019s molecular target. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Evidence context: Human trial evidence for omega\u20113/DHA improving cognition is mixed and systematic reviews found no clear cognitive benefit in mild\u2011to\u2011moderate Alzheimer\u2019s or in prevention trials to date, supporting classification as a cognitive/nutritional intervention with uncertain efficacy. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: Given the intervention (a dietary omega\u20113 fatty acid), its mechanism (structural/neuronal membrane and neuroprotective roles) and the trial focus (brain delivery and cognition), the best fit among the provided categories is 'cognitive enhancer' rather than a disease\u2011targeted biologic or small molecule that specifically targets Alzheimer\u2019s pathology. No indication this is a diagnostic/non\u2011therapeutic study that would warrant 'N/A.' \ue200cite\ue202turn0search0\ue202turn1search12\ue201"
    ],
    "agent_type": "C) ApoE, Lipids and Lipoprotein Receptors",
    "explanation_agent": [
        "Reason: The intervention is docosahexaenoic acid (DHA), an omega\u20113 long\u2011chain polyunsaturated fatty acid (a lipid) that acts in the brain by incorporation into membrane phospholipids, modulating membrane/protein function, supporting synaptic development and exerting neuroprotective/anti\u2011inflammatory effects. \ue200cite\ue202turn0search6\ue202turn0search5\ue201",
        "Act: Because DHA is a lipid nutrient whose actions in brain depend on lipid transport/metabolism and interact with apolipoprotein\u2011related pathways (ApoE, lipoprotein trafficking, lipid species in CSF/plasma), the most specific CADRO fit is C) ApoE, Lipids and Lipoprotein Receptors rather than a direct amyloid/tau or purely synaptic category. (Clinical efficacy for cognition is mixed, consistent with a nutritional/lipid\u2011pathway intervention rather than a targeted disease\u2011modifying biologic). \ue200cite\ue202turn0search2\ue202turn0search7\ue202turn0search0\ue201",
        "Reflect: This classification aligns with the trial\u2019s emphasis on delivering a lipid (DHA) to the brain and the known biology linking DHA to brain lipid metabolism and ApoE\u2011dependent transport. An alternative plausible category would be M) Synaptic Plasticity/Neuroprotection (DHA supports synaptogenesis and neuroprotection), but CADRO\u2019s explicit lipid/ApoE grouping makes C the more specific choice. If the trial had targeted a defined inflammatory receptor only (e.g., GPR120) or focused solely on synaptic endpoints without lipid\u2011metabolism rationale, a different category might be chosen. \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Web search summary (key sources used): 1) Cochrane systematic review: omega\u20113 supplements showed no clear cognitive benefit in mild\u2011to\u2011moderate AD trials (evidence mixed/negative). \ue200cite\ue202turn0search0\ue201 2) Mechanistic reviews: DHA is taken up into brain phospholipids, modulates membrane domains and signaling relevant to neuroprotection and synaptic function. \ue200cite\ue202turn0search6\ue202turn0search5\ue201 3) Lipid/ApoE links: clinical and translational studies show DHA distribution to brain lipids is influenced by ApoE and lipoprotein pathways. \ue200cite\ue202turn0search2\ue202turn0search7\ue201 4) Anti\u2011inflammatory signaling: DHA can act via receptors such as GPR120 to mediate anti\u2011inflammatory effects in neural cells. \ue200cite\ue202turn0search4\ue201"
    ]
}